Article thumbnail

What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale

By Anja Görtz-Dorten, Dieter Breuer, Christopher Hautmann, Aribert Rothenberger and Manfred Döpfner

Abstract

Satisfaction with medication is important in the evaluation of overall treatment outcome. There is a lack of consistent and validated rating scales for satisfaction with medication in ADHD, therefore comparison across studies is difficult. Here, we analyse the psychometric properties of the satisfaction with medication scale (SAMS), a new item-based questionnaire that assesses satisfaction with ADHD medication. Furthermore, we evaluate the predictive effect of ADHD symptoms and quality of life (QoL) on satisfaction. Data on satisfaction with Equasym XL® (methylphenidate) were collected in the OBSEER study using the parent (SAMS-P, n = 589) and patient (SAMS-S, n = 552) versions of the SAMS questionnaire. Internal consistency, item-total and cross-informant correlations, and the stability of satisfaction ratings over time were assessed. Satisfaction with medication scores were then correlated with ratings of ADHD symptoms and QoL. Rates of overall satisfaction with Equasym XL® among parents and children were high (>70%), as was internal consistency for both SAMS-P and SAMS-S (Cronbach’s alpha > 0.9). Similarly, item-total correlations were high (r = 0.71–0.90) for SAMS-P and medium–high (r = 0.57–0.77) for SAMS-S. Cross-informant correlations and the stability of satisfaction ratings were moderate (r = 0.54–0.59 and 0.48–0.60, respectively). ADHD symptom and QoL ratings were significantly negative and positive predictors of satisfaction, explaining 36–52% of satisfaction variance at the final visit. The results show that parent and patient satisfaction was high and could be assessed reliably with the new SAMS questionnaire. Parent and patient ratings were moderately correlated, and symptom severity, functional impairment and QoL were the most significant predictors of satisfaction

Topics: Supplement
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3180627
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/ hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 14:305–309
  2. (2011). A
  3. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.
  4. (2002). A postmarketing clinical experience study of Metadate CD.
  5. (2006). A randomized, controlled effectiveness trial of OROSmethylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
  6. (2011). An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. Eur Child Adolesc Psychiatry.
  7. (1998). Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results.
  8. (2011). Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. Eur Child Adolesc Psychiatry.
  9. (2000). Attention-deficit and disruptive behavior disorders. Attention-deficit/hyperactivity disorder. Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association,
  10. (2005). Attention-deficit hyperactivity disorder.
  11. (2007). Changes and challenges: managing ADHD in a fast-paced world.
  12. (1998). Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.
  13. (2009). Children’s self-reports on perceived effects on taking stimulant medication for ADHD.
  14. (2006). Comparison of the clinical efficacy of twicedaily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 15:450–459
  15. (2000). Der Fremdbeurteilungsbogenfu ¨rhyperkinetischeSto ¨rungen(FBB-HKS)— Pra ¨valenz hyperkinetischer Sto ¨rrungen im Elternurteil und psychometrische Kriterien. Kindheit und Entwicklung 9.
  16. (1993). Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance.
  17. (2001). Once-a-day Concerta methylphenidate versus three-timesdaily methylphenidate in laboratory and natural settings. Pediatrics 107:E105
  18. (2003). Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder.
  19. (2008). Psychometric properties of two ADHD questionnaires: comparing the Conners’ scale and the FBB-HKS in the general population of German children and adolescents—results of the BELLA study.
  20. (2001). Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
  21. (1992). Relationship of clients’ reasons for dropping out of treatment to outcome and satisfaction.
  22. (2005). Review and comparison of the long acting methylphenidate preparations.
  23. (2004). Satisfaction with treatment for attentiondeficit/hyperactivity disorder.
  24. (1995). The acceptability of interventions for attention-deficit hyperactivity disorder among elementary and middle school teachers.
  25. (2002). The impact of dosing frequency on psychostimulant compliance in ADHD. In:
  26. (2007). The worldwide prevalence of ADHD: a systematic review and metaregression analysis.
  27. (1992). World Health Organization
  28. (2010). Young people’s experience of ADHD and stimulant medication: a qualitative study for the NICE guideline. Child Adolesc Ment Health 15:186–192